Anti-Human CD307e (FcRL5) – Purified in vivo PLATINUM™ Functional Grade

Pricing & Details

Product No.I-2100
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
CD307e, CD307, BXMAS1, FCRH5, Fc receptor-like protein 5, IRTA2
IgG2a κ
Prod No.
Add to cart
I-2100-1.0 mg
1.0 mg
In stock
Min: 1
Step: 1
I-2100-5.0 mg
5.0 mg
In stock
Min: 1
Step: 1
I-2100-25 mg
25 mg
In stock
Min: 1
Step: 1
I-2100-50 mg
50 mg
In stock
Min: 1
Step: 1
I-2100-100 mg
100 mg
In stock
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Antibody Details

Product Details

Reactivity Species
Host Species
Cells transfected with Human FcRL5.
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 0.5 EU/mg as determined by the LAL method
≥98% monomer by analytical SEC
>95% by SDS Page
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUMTM antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this CD307e antibody for staining cells in flow cytometry is ≤ 0.125 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Other Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


Clone 50946 recognizes human FcRL5 within the first 3 Ig domains. Clone 50946 does not cross-react with FcRL4.
Antigen Distribution
FcRL5 is expressed on mature B cells and plasma cells.
FcRL5 antibody, 509F6, recognizes Fc receptor-like 5 (FcRL5), also known as immunoglobulin superfamily receptor translocation associated 2 (IRTA2), Fc receptor homolog 5 (FcRH5), and BXMAS1. FcRL5 is a 106 kDa type I transmembrane glycoprotein containing 9 Ig-like extracellular domains, a cytoplasmic ITAM-like consensus sequence, and two cytoplasmic ITIM-like sequences1. FcRL5 is found on most mature B cells, with the highest levels on naive and memory B cells and plasma cells1,2. FcRL5 is an IgG receptor and binds to all IgG isotypes3, resulting in the inhibition of BCR signaling through the recruitment of SH2 domain-containing tyrosine phosphatase 1 (SHP-1) after tyrosine phosphorylation of its two ITIMs4. B cell malignancies, including multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, and hairy cell leukemia, often exhibit aberrant FCRL5 expression, indicating FcRL5 as a potential biomarker or therapeutic target5-7.

Antigen Details

Aggregated IgG
NCBI Gene Bank ID

References & Citations

1. M. D. Cooper., et al. (2001). Proc. Natl. Acad. Sci. USA 98: 9772–9777
2. Koeppen H., et al. (2006) Int Immunol. 18:1363-1373
3. Colonna M., et al. (2012) J Immunol. 188(10):4741-5
4. M. D. Cooper., et al (2007) Proc. Natl. Acad. Sci. USA 104: 9770–9775
5. Dalla-Favera R., et al. (2001) Immunity. 14(3):277-89
6. Pastan I., et al. (2007) Leukemia. 21(1):169-74
7. Nagata S., et al. (2005) Clin Cancer Res. 11(1):87-96
Flow Cytometry
Immunoprecipitation Protocol

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.